Open Flow Microperfusion as a Dermal Pharmacokinetic Approach to Evaluate Topical Bioequivalence
In many countries, strategies to control healthcare spending rely upon the availability and use of generic medicines.
The safety and effectiveness of high-quality generic medicines is ensured through a demonstration of bioequivalence (BE).
The methodology for assessing the BE of systemically absorbed drugs and for the statistical assessment of comparative systemic bioavailability (BA) based upon pharmacokinetic (PK) endpoints is well established.
Download to find out more.